<DOC>
	<DOC>NCT01412151</DOC>
	<brief_summary>The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.</brief_summary>
	<brief_title>Creatine Safety &amp; Tolerability in Huntington's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Individuals who have completed the CRESTUP1 study. Individuals who are able to take oral medication. Individuals capable of providing informed consent and complying with trial procedures. History of known sensitivity or intolerability to creatine. Clinical evidence of unstable medical illness in the investigator's judgment. Additional eligibility criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Symptomatic</keyword>
	<keyword>Huntington's Disease</keyword>
	<keyword>HD</keyword>
</DOC>